scholarly journals Pseudomyxoma Peritonei Originating from Transverse Colon Mucinous Adenocarcinoma: A Case Report and Literature Review

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Yingbo Gong ◽  
Xin Wang ◽  
Zhi Zhu
Keyword(s):  
Literature Review ◽  
Pseudomyxoma Peritonei ◽  
Transverse Colon ◽  
Mucinous Adenocarcinoma ◽  
Lung Metastases ◽  
Metastatic Cancer ◽  
Genetic Profile ◽  
Low Grade ◽  
Extensive Literature ◽  
Cancer Multiple

Background. Pseudomyxoma peritonei (PMP) is a rare neoplasm involving the peritoneum. Most PMPs are low-grade appendicular mucinous neoplasms (LAMNs). There have been no reports of PMP originating from a transverse colonic mucinous adenocarcinoma and causing metastatic mucinous adenocarcinoma. Case Presentation. We report a 46-year-old woman who presented with a right abdominal mass of more than 4-month duration. Transverse colonic mucinous adenocarcinoma, PMP, and ovarian metastatic mucinous adenocarcinoma were diagnosed. The patient’s diet was normal, and she had no abdominal pain or bloating. The abdomen mass increased in the month before treatment. After chemotherapy, the transverse colon mass and ovarian giant cyst were resected and about 2000 mL of gelatinous tumor tissue was removed. Postoperative histology confirmed PMP from the transverse colonic mucinous adenocarcinoma, ovarian metastatic mucinous adenocarcinoma, and mesocolon metastatic cancer. Multiple lung metastases appeared 8 months after surgery. The patient died 29 months after surgery because of an inability to eat and poor nutrition. A systematic literature review of the management and outcome of all known similar cases is also presented. Conclusions. This is the first report of PMP originating from a transverse colonic mucinous adenocarcinoma. It was diagnosed during resective surgery, involved ovarian metastasis, and survival was short. We did an extensive literature review in order to describe the clinical characteristics, histopathological findings, genetic profile, and potential treatments of PMP caused by nonappendiceal mucinous adenocarcinoma.

scholarly journals EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review

Sarcoma ◽  
2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Beata Bode-Lesniewska ◽  
Christine Fritz ◽  
Gerhard Ulrich Exner ◽  
Ulrich Wagner ◽  
Bruno Fuchs
Keyword(s):  
Literature Review ◽  
Ewing Sarcoma ◽  
Soft Tissues ◽  
Clinical Aspects ◽  
Low Grade ◽  
Extensive Literature ◽  
Mesenchymal Tumors ◽  
Detection Techniques ◽  
Gene Translocation ◽  
The Many

The spectrum of mesenchymal tumors associated with rearrangements of the EWSR1 gene has been growing in recent years due to progress in molecular detection techniques. Originally identified as the gene involved in the pathogenesis of Ewing sarcoma, the EWSR1 gene is now known to be rearranged in diverse clinical and histopathological entities. The NFATC2 gene is one of the many translocation partners of EWSR1 in gene fusions in a morphologically typical, albeit rare, subgroup of mesenchymal tumors. Little is known about the clinical characteristics of tumors containing NFATC2 gene rearrangements since most of the few reports published describe molecular rather than clinical aspects. In the current study, we report three patients with tumors carrying the EWSR1-NFATC2 gene translocation, including one rare primary tumor of soft tissues. Another patient with a benign-appearing bone tumor with a unique FUS-NFATC2 gene translocation is described. In various mesenchymal tumors (e.g., myxoid/round cell liposarcoma, low-grade fibromyxoid sarcoma, or angiomatoid fibrous histiocytoma), the FUS gene, as a member of the TET family, may be alternatively rearranged instead of the EWSR1 gene without any noticeable influence on the microscopical appearance or clinical outcome. This fact seems not to apply to mesenchymal tumors with the involvement of the NFATC2 gene because both in our experience and according to the extensive literature review, they have different properties on the morphological and molecular level. Both ESWSR1-NFATC2 and FUS-NFATC2 fusion-carrying tumors do not show microscopical or clinical features of Ewing sarcoma.

scholarly journals Primary low-grade mucinous adenocarcinoma spleen resulting in Pseudomyxoma peritonei: A case report

2020 ◽  
Vol 63 (2) ◽  
pp. 286
Author(s):  
Richa Jindal ◽  
Bhumika Gupta ◽  
Molly Joseph ◽  
Kuldeep Kaur ◽  
Shikha Chopra ◽  
...  
Keyword(s):  
Case Report ◽  
Pseudomyxoma Peritonei ◽  
Mucinous Adenocarcinoma ◽  
Low Grade

Genetic Alterations in Chinese Resected Lung Cancer with Invasive Mucinous Adenocarcinoma: Genomic Profiling and Prognostic Value Analysis

2021 ◽  
Author(s):  
James D. Klingensmith
Keyword(s):  
Mucinous Adenocarcinoma ◽  
Pi3k Pathway ◽  
Genetic Alterations ◽  
Egfr Mutations ◽  
Driver Mutations ◽  
Genetic Profile ◽  
Kras Mutations ◽  
Genetic Characteristics ◽  
Value Analysis ◽  
Invasive Mucinous Adenocarcinoma

Lung invasive mucinous adenocarcinoma (IMA) is a unique histological subtype with different clinical and pathological characteristics. Despite prior genomic investigations on lung IMA, little is known about the genetic features and prognosis-related biomarkers in Chinese surgically resected lung IMA. IMA showed a distinct genetic profile, with more diversified driver mutations and co-occurrence of tumor drivers/suppressors than non-IMA. From non-IMA to mixed-IMA to pure-IMA, the frequency of EGFR (72.0 percent vs. 40.0 percent vs. 23.1 percent, p=0.002) and ALK (undetected vs. 20.0 percent vs. 26.9%, p=0.015) changes exhibited a trend of steady decline and rise, respectively. KRAS mutations were more common in pure-IMA than in mixed-IMA, however the difference was statistically insignificant (23.1 percent vs. 4.0 percent, p=0.10). Pure-IMA had a lower rate of TP53 mutation than mixed-IMA and non-IMA (23.1 percent vs. 52.0 percent vs. 56.0 percent, p=0.03). Furthermore, IMA had fewer arm-level amplifications (p=0.04) and more arm-level deletions (p=0.004) than non-IMA, with a steady drop in amplification and rise in deletion frequency from non-IMA to mixed-IMA to pure-IMA, respectively. Patients with EGFR mutations (mDFS=30.3 vs. 16.0 months, HR=0.19, P=0.027) and PI3K pathway mutations (mDFS=36.0 vs. 16.0 months, HR=0.12, P=0.023) had longer DFS than patients with poorly differentiated tumors (mDFS=14.1 vs. 28.0 months, HR=3.75, p=0.037) or KRAS mutations (mDFS=13 KRAS mutations, PI3K pathway changes, and tumor differentiation status were all shown to be independent predictors with statistically significant effects on IMA patients' clinical outcomes in multivariate analysis. Our research shed light on the genomics of Chinese lung IMA that had been surgically removed. In IMA patients with stage III illness, we also discovered many genetic characteristics that might be used as indicators for postoperative recurrence.

Metastasis of the right colon mucinous adenocarcinoma to aortocaval and retropancreatic space: case report and literature review

2021 ◽  
pp. 95
Author(s):  
A.L. Bedzhanyan ◽  
M.I. Bredikhin ◽  
T.N. Galyan ◽  
D.E. Arutyunyants ◽  
K.N. Petrenko ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Mucinous Adenocarcinoma ◽  
Right Colon ◽  
Space Case ◽  
The Right

Die kognitive Legitimität aus Kundensicht im Kontext neuer Unternehmen

2021 ◽  
Author(s):  
Miriam Lohrmann
Keyword(s):  
Literature Review ◽  
Three Dimensional ◽  
Dimensional Structure ◽  
Extensive Literature ◽  
Extensive Literature Review ◽  
New Business ◽  
Potential Customers ◽  
Cognitive Legitimacy

Customer cognitive legitimacy is an important factor in a new business venture’s survival. Based on an extensive literature review of customer cognitive legitimacy, this book examines the consistent conceptualisation of the concept and its dimensional structure. This consistent conceptualisation facilitates the development of the reliable and valid three-dimensional customer cognitive legitimacy scale in 10 studies. The scale is based on potential customers’ interest in acquiring knowledge about a product and the company responsible for it, their perception of the company’s and the product’s future, and their perception of how competent the company’s managers are.

Sign in / Sign up

Export Citation Format

Share Document